The Cali Fund, a global biodiversity financing mechanism intended to secure $1 billion a year from companies that profit from nature’s genetics, has raised just $7,000 more than 18 months after it was launched, according to reporting by the Guardian. Campaigners and observers have accused major pharmaceutical companies of “free‑riding on nature” amid the fund’s near‑empty coffers.
The fund was established to persuade businesses that derive value from genetic resources in nature to contribute a share of profits toward conservation and benefit‑sharing projects in low‑income countries. Its backers set the goal of collecting $1 billion annually (reported as about £750 million) to support biodiversity protection and help meet global conservation targets.
Despite that ambition, the fund’s reported receipts remain minimal. More than a year and a half after the Cali Fund was announced, it has attracted only $7,000, leaving it far below the original target and prompting criticism about the willingness of the private sector — and particularly pharmaceutical firms — to contribute.
Why the shortfall matters
Supporters of the Cali Fund framed it as a way to ensure companies that profit from genetic resources help address the global biodiversity crisis and support communities in countries where those resources originate. Proponents say steady, predictable financing is needed to back conservation programs, restore ecosystems and compensate local custodians of biodiversity.
The failure to attract meaningful contributions raises questions about the practicality of voluntary industry levies and the capacity of voluntary funds to capture revenues from high‑value commercial uses of biodiversity. Critics argue that if the companies benefiting most from natural genetic resources do not provide funding, the burden of conservation will continue to fall on governments and donors with limited resources.
Responses and next steps
The reporting does not list responses from pharmaceutical companies or fund administrators about the shortfall. It also does not detail any planned enforcement mechanisms, mandatory contributions or changes to the fund’s design to increase uptake.
Observers and campaigners have used the fund’s low take‑up to highlight perceived gaps between rhetoric and action on corporate responsibility for biodiversity. How fund managers and stakeholders respond — by altering incentives, pursuing binding instruments, or seeking alternative financing models — will determine whether the Cali Fund can still grow into the predictable revenue stream its creators envisioned.
The outcome has implications beyond a single fund: as nations and organisations seek sustainable financing to meet international biodiversity targets, the willingness of private‑sector beneficiaries to share gains from nature remains a central and unresolved challenge.